breast cancer Archive — Page 11 of 22
-
October 26, 2017
Study to test combination therapy for breast cancer
Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer. -
August 9, 2017
Breast Cancer Genomic Profiling Reveals Clues to Treatment Resistance
Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers. -
August 9, 2017
Stress may switch on bone “mets”
New findings could explain the link between chronic stress and reduced survival in women diagnosed with breast cancer, and could lead to new strategies to improve treatment outcomes. -
August 3, 2017
Investigators match novel cancer mutations with potential therapies
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. -
July 20, 2017
Drivers of breast cancer metastasis
Signaling through a complex of proteins called mTORC2 plays a role in breast cancer migration, invasion and metastasis, Vanderbilt researchers reported. -
July 13, 2017
Arteaga to direct UT Southwestern cancer center
Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas. -
June 19, 2017
STINGing combination for cancer
A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.